Akari Partners with WuXi XDC on Novel Cancer Therapy

Akari Therapeutics Plc has announced a strategic partnership with WuXi XDC to accelerate the development of its next-generation antibody-drug conjugate (ADC) technology, marking a significant step forward in its oncology pipeline.

The collaboration will focus on advancing Akari’s proprietary PH1 payload, a novel RNA splicing modulator designed to enhance the effectiveness of ADC therapies. The partnership brings together Akari’s innovative payload technology with WuXi XDC’s established expertise in ADC development and manufacturing, aiming to fast-track the progression of Akari’s lead candidate, AKTX-101.

Akari’s CEO, Abizer Gaslightwala, described the agreement as a major milestone for the company, emphasizing that WuXi XDC’s reputation in ADC innovation validates the potential of the PH1 platform. He noted that the partnership is expected to help accelerate development timelines and further demonstrate the clinical promise of the technology.

WuXi XDC’s leadership echoed this sentiment, highlighting the growing need for innovation in ADC payloads to improve treatment outcomes. The company has a track record of supporting the development of novel ADC therapies and aims to help bring first-in-class treatments to patients through collaborations like this.

AKTX-101, Akari’s lead program, is initially being developed for metastatic urothelial cancer, a condition with limited treatment options, particularly for patients who do not respond to first-line therapies. Current second-line treatments often rely on chemotherapy, which provides only modest clinical benefit. Akari believes that its novel approach could offer a more effective alternative for these patients.

The PH1 payload represents a new direction in ADC design. Unlike traditional payloads that typically rely on microtubule inhibitors or DNA-damaging agents, PH1 works by disrupting RNA splicing within cancer cells. This mechanism not only induces direct tumor cell death but may also stimulate both innate and adaptive immune responses, potentially enhancing overall anti-cancer activity.

Preclinical studies of AKTX-101 have shown encouraging results, including strong tumor regression and complete remissions when compared to existing ADC approaches. These findings suggest that PH1 could form part of a new generation of ADC payloads with improved efficacy and broader therapeutic potential.

Akari plans to advance AKTX-101 into a Phase 1 clinical trial, expected to begin in late 2026 or early 2027, pending regulatory approval. This upcoming milestone will be critical in determining the safety and effectiveness of the therapy in humans.

The partnership reflects a broader trend in oncology research, where companies are increasingly exploring novel mechanisms and technologies to overcome the limitations of existing treatments. By combining innovative science with specialized development capabilities, Akari and WuXi XDC aim to deliver more effective therapies for patients with difficult-to-treat cancers.